ThinkPatternGet the app
Story
BUSINESS · NOV 20, 2026

Novartis CEO Warns U.S. Biotech Investment Curbs Delay Drugs

Novartis CEO Vas Narasimhan warns that proposed U.S. Treasury restrictions on biotech investments in China could hinder the development of new medications.

Novartis CEO Vas Narasimhan warned that proposed U.S. government restrictions on biotechnology investments in China could delay the development of new medications. Speaking to Bloomberg TV on Friday, Narasimhan stated that Treasury Department limits would hinder the transfer of technologies between U.S. and Chinese operations, potentially limiting patient access to new discoveries.

Narasimhan argued that finding treatments for heart disease or cancer is not a national security issue. He noted that the current approach would limit the ability to bring technologies into U.S. factories for U.S. patients and vice versa. He expressed hope that more sensible approaches would emerge from ongoing discussions.

The U.S. Treasury Department proposed in October to include biotechnology in the Comprehensive Outbound Investment National Security (COINS) Act. This act already caps investments in semiconductors, quantum computing, and artificial intelligence. These rules could impact foreign drugmakers with U.S. operations, including Novartis. The Swiss-headquartered company recently signed a licensing agreement worth up to $7.8 billion with Chinese developer Abogen Biosciences for an mRNA-encoded autoimmune therapy.


Reported across 2 outlets
Actors
Vas NarasimhanNovartis AGUnited States Department of the TreasuryAbogen Biosciences

Keep reading in the app

The full story and every source, free in the app.